Gland Pharma Board of Directors

Get the latest insights into the leadership at Gland Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Srinivas Sadu Executive Chairman
Mr. Wenjie Zhang Non Exe.Non Ind.Director
Mr. Wei Huang Non Exe.Non Ind.Director
Dr. Jia Ai (Allen) Zhang Non Exe.Non Ind.Director
Mr. Essaji Goolam Vahanvati Independent Director
Mr. Udo Johannes Vetter Independent Director
Mr. Satyanarayana Murthy Chavali Independent Director
Ms. Naina Lal Kidwai Independent Director

Gland Pharma Share price

GLAND

1885.3

8.50 (0.45%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:29 IST
BUYSELL
Today's High

1903.90

Today's Low

1865.10

52 Week Low

1277.80

52 Week High

2131.00

The current prices are delayed, login to your account for live prices

Gland Pharma FAQs

The board at Gland Pharma consists of experienced professionals, including Mr. Srinivas Sadu , Mr. Wenjie Zhang , and others, overseeing the company’s strategic and corporate governance.

Directors at Gland Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Srinivas Sadu is the current chairman at Gland Pharma.

Executive directors at Gland Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Gland Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Gland Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.